Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
March 29 2022 - 8:35AM
Business Wire
– Live video webcast with moderated fireside
chat with members from the Cyclo Therapeutics management team and
featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday,
April 5th at 1:00 PM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a late clinical stage biotechnology company
dedicated to developing life-changing medicines through science and
innovation for patients and families living with diseases, today
announced it will participate in the Virtual Investor Alzheimer’s
Disease Spotlight event on Tuesday, April 5, 2022 at 1:00 PM
ET.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220329005103/en/
Cynthia A. Lemere, PhD (Photo: Business
Wire)
For the fireside chat, N. Scott Fine, Chief Executive Officer,
and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo
Therapeutics will be joined by Alzheimer’s Disease Key Opinion
Leader, Cynthia A. Lemere, PhD.
Dr. Lemere is a preeminent neuroscientist, world-renowned
researcher, and recently appointed as Senior Advisor for
advancement of Cyclo Therapeutics’ Alzheimer’s disease asset.
As part of the event, Cyclo Therapeutics will discuss its
development program of Trappsol® Cyclo™ for the treatment of
Alzheimer’s disease. The Company recently received clearance of its
investigational new drug (“IND”) application from the U.S. Food and
Drug Administration (“FDA”) to proceed with its Phase 2 study of
Trappsol® Cyclo™ for the treatment of early Alzheimer’s
disease.
Trappsol® Cyclo™ is the Company’s proprietary formulation of
hydroxypropyl beta cyclodextrin, and in multiple clinical studies,
has shown encouraging results to effectively manage the
transportation of cholesterol. Many of the known risk factors for
Alzheimer’s disease are associated with cholesterol metabolism.
Cholesterol imbalance in Alzheimer’s patients is well known, and
significant research exists, suggesting these imbalances are
responsible for amyloid beta (Aβ) and tau accumulation.
Furthermore, neurons, because of their high metabolic demands,
experience an increased level of oxidative stress. Oxidative stress
has also been linked to abnormal cholesterol accumulation and
processing.
A live video webcast of the spotlight event will be available on
the Events page of the Investors section of the Company’s website
(cyclotherapeutics.com). A webcast replay will be available two
hours following the live presentation and will be accessible for 90
days.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a late clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is being studied in a
Phase 3 pivotal clinical trial for Niemann-Pick Disease Type C, a
rare and fatal genetic disease, (www.ClinicalTrials.gov
NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company
is planning a Phase 2 clinical trial using Trappsol® Cyclo™
intravenously in Alzheimer’s Disease based on encouraging data from
an Expanded Access program for late-onset Alzheimer’s Disease
(NCT03624842). Additional indications for the active ingredient in
Trappsol® Cyclo™ are in development. For additional information,
visit the Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220329005103/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Sep 2023 to Sep 2024